U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C29H40FN5O2
Molecular Weight 509.6586
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PF-232798

SMILES

CC(C)C(=O)N1CCC2=C(C1)N=C(C)N2[C@@H]3C[C@@H]4CC[C@H](C3)N4CC[C@H](NC(C)=O)C5=CC=CC(F)=C5

InChI

InChIKey=QETUKYDWZIRTEI-QUMGSSFMSA-N
InChI=1S/C29H40FN5O2/c1-18(2)29(37)33-12-11-28-27(17-33)31-19(3)35(28)25-15-23-8-9-24(16-25)34(23)13-10-26(32-20(4)36)21-6-5-7-22(30)14-21/h5-7,14,18,23-26H,8-13,15-17H2,1-4H3,(H,32,36)/t23-,24+,25+,26-/m0/s1

HIDE SMILES / InChI

Molecular Formula C29H40FN5O2
Molecular Weight 509.6586
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

PF-232798 is a potent oral CCR5 antagonist with a primary and selectivity/safety pharmacology profile similar to maraviroc (MVC). PF-232798 shows increased binding affinity and improved oral absorption compared to maraviroc. In addition, it retains activity against a laboratory generated maraviroc-resistant HIV-1 strain, indicating an alternative drug resistance profile. PF-232798 binds to the same pocket as MVC within the transmembrane region of CCR5, but shows additional interactions at the ECL2 hinge region. PF-232798 is well tolerated in normal volunteers. PF-232798 had been in a phase-II clinical trial for the treatment of HIV infections. However, this development was discontinued.

Approval Year

PubMed

PubMed

TitleDatePubMed
An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798).
2011 Jan 13
Molecular binding mode of PF-232798, a clinical anti-HIV candidate, at chemokine receptor CCR5.
2019 Apr
Patents

Sample Use Guides

250mg QD, 7 days dosing
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 05:32:09 GMT 2023
Edited
by admin
on Sat Dec 16 05:32:09 GMT 2023
Record UNII
63P7W7886U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PF-232798
Common Name English
ACETAMIDE, N-((1S)-1-(3-FLUOROPHENYL)-3-((3-ENDO)-3-(4,5,6,7-TETRAHYDRO-2-METHYL-5-(2-METHYL-1-OXOPROPYL)-1H-IMIDAZO(4,5-C)PYRIDIN-1-YL)-8-AZABICYCLO(3.2.1)OCT-8-YL)PROPYL)-
Common Name English
PF-00232798
Common Name English
Code System Code Type Description
CAS
849753-15-7
Created by admin on Sat Dec 16 05:32:09 GMT 2023 , Edited by admin on Sat Dec 16 05:32:09 GMT 2023
PRIMARY
EPA CompTox
DTXSID40234029
Created by admin on Sat Dec 16 05:32:09 GMT 2023 , Edited by admin on Sat Dec 16 05:32:09 GMT 2023
PRIMARY
PUBCHEM
53316710
Created by admin on Sat Dec 16 05:32:09 GMT 2023 , Edited by admin on Sat Dec 16 05:32:09 GMT 2023
PRIMARY
FDA UNII
63P7W7886U
Created by admin on Sat Dec 16 05:32:09 GMT 2023 , Edited by admin on Sat Dec 16 05:32:09 GMT 2023
PRIMARY
DRUG BANK
DB14813
Created by admin on Sat Dec 16 05:32:09 GMT 2023 , Edited by admin on Sat Dec 16 05:32:09 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY